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Purpose
To identify what participants in major RCTs in the UK
are told about placebos and their effects.
Methods
The major registry of current clinical trials in the UK
(UKCRN) was searched to identify trials conducted in
clinical populations using placebo controls. Emails were
sent to 182 contact personnel requesting they send their
participant information leaflets (PILs) for inclusion in the
study. Forty-nine PILs were received; 45 were included in
the analysis (4 were ineligible). Qualitative and quantita-
tive techniques of content analysis were used to identify
characteristics of the trials, how the placebo and target
treatment were explained, the presence or absence of
information about possible effects of the target and pla-
cebo treatments, and options concerning un-blinding
and possible treatments after the trial.
Results
Placebos and target treatments were described quite differ-
ently. In almost every comparison, the target treatments
were prioritized over the placebo, from the words in the
title to the description of what would happen at the end of
the trial. The placebo was described as a scientific tool that
would allow efficacy of the target treatment to be deter-
mined; the target treatment was described as a treatment
that might generate health effects. Placebo treatments were
referred to less frequently than target treatments and were
significantly less likely to be described as triggering either
positive or adverse health effects (p<.01). A minority of
PILs mentioned un-blinding or treatment options after the
trial, and the focus of the latter was primarily on the possi-
bility of continuing with the target treatment.
Conclusion
Trial participants were poorly informed about the health
changes that they might experience if they were allocated
to a placebo treatment, and of options that might be avail-
able to them after the trial. Different ways of describing
placebos to participants, in PILs and in person, should be
developed and tested.
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